Combination drugs for advanced nerve sheath tumors
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This trial tests two drugs, avutometinib and defactinib, given together to treat a rare type of nerve tumor (MPNST) that has come back or spread. The goal is to see if this combination can shrink or control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be older than 12 years and have a body surface area (a measure of your size) of at least 1.5 square meters.
- You must have a confirmed diagnosis of MPNST (malignant peripheral nerve sheath tumor) that is either linked to NF1 or not, and it must have come back, spread, or be unable to be removed with surgery.
- You must have had at least one prior chemotherapy treatment, or you must have declined chemotherapy.
- You must have at least one tumor that can be measured on a scan.
- You must have good enough organ function, including blood counts, liver, kidney, and heart function, as determined by blood tests and other evaluations.
- You must have fully recovered from the side effects of any prior cancer treatments, meeting specific waiting periods (e.g., at least 2 weeks after chemotherapy, 4 weeks after immunotherapy, etc.).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two targeted drugs (selumetinib and milademetan) for people with neurofibromatosis type 1 (NF1) who have either a malignant peripheral nerve sheath tumor (MPNST) or an atypical neurofibromatous neoplasm with uncertain biologic potential (ANNUBP). The goal is to see if blocking certain proteins can shrink or control these tumors.
This study tests whether a new drug called BMS-986504 is safe and effective for treating malignant peripheral nerve sheath tumors (MPNST) that cannot be surgically removed. The drug targets a specific genetic change (MTAP deletion) found in these tumors.
This trial tests two targeted drugs, mirdametinib and vorinostat, to see if they can shrink MPNST tumors in people with NF1 before surgery. It is for patients whose tumors lack a specific protein marker (H3K27me3).
This trial tests a combination of two targeted drugs (defactinib and avutometinib) plus an immunotherapy (nivolumab) for people with advanced lung adenocarcinoma that has a specific gene mutation (LKB1) and has stopped responding to prior immunotherapy and chemotherapy. The goal is to see if this new combination can shrink tumors or slow cancer growth.
This trial tests a combination of two oral medications for people who have just been diagnosed with a high-grade brain tumor. The goal is to see if the treatment is safe and feasible when given alongside standard radiation therapy.
This trial tests two oral drugs, avutometinib and defactinib, in people with aggressive brain tumors like glioblastoma. The goal is to see if this combination can shrink tumors or stop them from growing.
Hear when a new MPNST (Malignant Peripheral Nerve Sheath Tumor) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.